EMT-related resistance to the EGFR inhibitor Erlotinib can be induced via nerve growth factor (NGF) and tropomyosin receptor kinase A TrkA), which are both elevated in HNSCC and predict poor survival [140]. The gene discussed is NTRK1; the disease is head and neck squamous cell carcinoma.